FINDING THE OPTIMAL TREATMENT STRATEGY FOR DISEASE ACTIVITY-GUIDED DOSE REDUCTION OF ADALIMUMAB AND ETANERCEPT IN RHEUMATOID ARTHRITIS: A MODELLING STUDY

被引：0
|
作者：
Verhoef, L. M. [1 ]
Bos, D. P. [1 ]
van den Ende, C. H. [1 ,2 ]
van den Hoogen, F. H. [1 ,2 ]
Fautrel, B. [3 ]
Hulscher, M. E. [4 ]
Kievit, W. [5 ]
den Broeder, A. A. [1 ,2 ]
机构：
[1] St Maartenskliniek, Rheumatol, Nijmegen, Netherlands
[2] Radboudumc, Rheumatol, Nijmegen, Netherlands
[3] Hop La Pitie Salpetriere, Rheumatol, Paris, France
[4] RIHS, IQ Healthcare, Nijmegen, Netherlands
[5] Radboudumc, RIHS, Hlth Evidence, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2604
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0207
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [21] DOSE REDUCTION OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY: A PILOT STUDY
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B.
    van Vollenhoven, R.
    Bijlsma, J.
    den Broeder, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 886 - 886
  • [22] MINOCYCLINE TREATMENT FOR RHEUMATOID-ARTHRITIS - AN OPEN DOSE FINDING STUDY
    BREEDVELD, FC
    DIJKMANS, BAC
    MATTIE, H
    JOURNAL OF RHEUMATOLOGY, 1990, 17 (01) : 43 - 46
  • [23] The effectiveness of etanercept and adalimumab on anemia of chronic disease and serum hepcidin in patients with rheumatoid arthritis, a comparative study
    Abu-Zaid, M. H.
    El Morsya, S.
    Rageh, E. M.
    Shahba, A.
    Gaber, R. A.
    EGYPTIAN RHEUMATOLOGIST, 2018, 40 (04): : 233 - 237
  • [24] Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B. J. F.
    van Vollenhoven, R. F.
    Bijlsma, J. W. J.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 390 - 394
  • [25] Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study
    van der Togt, Celeste J. T.
    den Broeder, Nathan
    Boonstra, Marleen S.
    van der Maas, Aatke
    den Broeder, Alfons A.
    van Herwaarden, Noortje
    RHEUMATOLOGY, 2024,
  • [26] Better disease activity states are achieved with etanercept treatment in patients with moderate rheumatoid arthritis vs severe rheumatoid arthritis
    Keystone, Edward
    Freundlich, Bruce
    Schiff, Michael
    Li, Juan
    Hooper, Michele
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S531 - S531
  • [27] DYNAMIC PREDICTION OF FLARES IN RHEUMATOID ARTHRITIS USING JOINT MODELLING AND MACHINE LEARNING: SIMULATION OF CLINICAL IMPACT WHEN USED AS DECISION AID IN A DISEASE ACTIVITY GUIDED DOSE REDUCTION STRATEGY
    Welsing, Paco
    den Broeder, Alfons
    Tekstra, Janneke
    van der Goes, Marlies
    Lafeber, Floris
    Jacobs, Johannes W. G.
    Medina, Oj
    Vodencarevic, Asmir
    Zimmermann-Rittereiser, Marcus
    Haitjema, Saskia
    van Laar, Jacob M.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1125 - 1126
  • [28] Disease activity-guided TNF inhibitor dose reduction was noninferior to continuing TNF inhibitors for RA flares
    Ramirez-Lafita, Francisco
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (06)
  • [29] Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
    Harigai, Masayoshi
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Matsubara, Tsukasa
    Yamanaka, Hisashi
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2012, 22 (06) : 814 - 822
  • [30] Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible
    van Herwaarden, Noortje
    Herfkens-Hol, Susan
    van der Maas, Aatke
    van Den Bemt, Bart J. F.
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    den Broeder, Alfons A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S992 - S992
12345